Physician profile
Nolleca Forbes-Thomas
NPI 1962828152
$1,550.07
in general payments reported to CMS, 2019-2025
13 companies · $736 in 2025
The $736 reported for 2025 was more than what 99% of Neonatal, Critical Care providers received nationally (typical 2025 total: $45.50).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $60.95 · 2023: $566 · 2024: $188 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,489.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $475.44 | 2023-2025 | Sapien 3 Ultra Resilia |
| Abbvie INC. | $333.33 | 2022-2025 | |
| Cardiva Medical, INC. | $171.86 | 2023 | Cardiva Vascade 6/7f Vcs |
| Teva Pharmaceuticals USA, INC. | $144.11 | 2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $134.56 | 2023 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.82 | 2022-2024 | Lifevest |
| Otsuka America Pharmaceutical, INC. | $64.62 | 2024 | Rexulti |
| Atricure, INC. | $44.99 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Medtronic, INC. | $30.43 | 2024-2025 | Corevalve Evolut R |
| Abiomed | $29.31 | 2025 | |
| Alkermes, INC. | $19.23 | 2025 | Vivitrol |
| Angiodynamics, INC. | $16.76 | 2023 | Angiovac |
| Indivior INC. | $15.61 | 2024 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nolleca Forbes-Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.